ClinicalTrials.gg
RecruitingNCT06407518POMPPRUpdated Apr 6, 2025

Preoperative Oral Midazolam to Postoperative Pain Relief in Sleep Disturbance or Anxiety Patients With Colorectal Cancer

An interventional study of Midazolam oral solution and Placebo in Preoperative, Sleep Disturbance and Anxiety, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-04-06.

Primary conditionPain, PostoperativeRegistry: Anxiety DisordersReclassifiedWhy we changed it
Registry
Anxiety Disorders — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pain, Postoperative
Why
  1. The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name Pain, Postoperative.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sixth Affiliated Hospital, Sun Yat-sen University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing midazolam in Pain, Postoperative — 3 open to participants now, 3 under way, none of them phase 3. Midazolam · Pain, Postoperative.

Planned enrollment
Largest of 13
280 · median 90
Started
2024
the only one that year
No phase
4 of 13
2 open now
Registered
12th of 13
by date
Lead sponsor
1 of 13
Sixth Affiliated Hospital, Sun Yat-sen University

Among the 13 studies testing midazolam in Pain, Postoperative, this one has the largest planned enrollment, is the only one that started in 2024, is one of 4 with no phase, and was the 12th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

3 of the 13 studies testing midazolam in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About midazolam

Midazolam: first FDA approval 1985 (VERSED), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing midazolam in Pain, Postoperative, or all of them as a file.
02

Study summary

Previous studies have indicated a high incidence of sleep disturbances and anxiety symptoms in individuals with colorectal cancers prior to undergoing surgery, leading to worsened postoperative pain, slower recovery, and higher risk of chronic pain. The enhancement of sleep quality is intricately linked to reducing stress. Preoperative drugs that combine hypnosis and anti-anxiety have not been studied in colorectal cancer patients. Midazolam oral solution is safe and effective for short-term hypnotic and anti-anxiety effects in clinical preoperative settings. In the current randomized controlled clinical trial, 280 patients experiencing sleep disturbance or anxiety prior to colorectal cancer surgery will receive midazolam solution to assess its potential efficacy in reducing postoperative pain, expediting recovery, and decreasing the likelihood of chronic pain. Additionally, the study aims to explore the potential connections between midazolam administration and reductions in stress and inflammation.

Read the detailed description

Preoperative sleep disturbance and anxiety worsen postoperative pain for patients undergoing surgeries. Research indicates that a significant proportion of patients, ranging from 8.8% to 79.1%, experience disturbances in sleep or anxiety prior to surgery. These preoperative issues have been shown to have lasting and intricate effects on postoperative pain, fatigue, and depression. Therefore, it is imperative for clinical doctors to promptly identify preoperative sleep disturbances and anxiety in order to offer appropriate support to patients.

Colorectal cancer is the fifth leading cause of death in China, with nearly 40% of patients experiencing insomnia before surgery, consistent with our previous studies. A case-control study demonstrated a protective association between improved sleep quality and relief of postoperative pain in colorectal cancers. Furthermore, individuals undergoing laparoscopic colorectal surgery showed a higher likelihood of experiencing visceral pain compared to somatic pain. Acute visceral pain has the potential to progress into chronic visceral pain, resulting in behavioral manifestations such as anxiety, fear, and depression, which may persist and exacerbate into enduring chronic pain, ultimately impacting the individual's quality of life. Currently, studies have shown that disturbed preoperative sleep has become a significant predictor of both acute and chronic postoperative pain. Therefore, finding effective interventions to promote preoperative sleep is a continuing consideration for clinicians.

Pharmacological intervention is the primary approach for preoperative sleep disturbances or anxiety. Finding appropriate drug is a challenge that needs to be solved in the clinical practice. There is currently a lack of evidence-based medical guidelines regarding pharmacologic interventions for preoperative sleep disturbances and anxiety. Research has indicated that zolpidem can enhance sleep quality in patients prior to surgery, decrease the need for analgesics during the procedure, and alleviate postoperative pain. Nevertheless, there is a demand for agents that possess both short-term hypnotic and anxiolytic properties, whereas zolpidem solely exhibits hypnotic effects. Midazolam, a short-acting benzodiazepine, is often used before anesthesia for its short-term hypnotic and anxiolytic effects. Studies have found that midazolam oral solution is safe and effective for short-term use in clinical pre-surgical settings. There are no studies on using oral midazolam solution to improve sleep and reduce anxiety in colorectal cancer patients before surgery. Our previous research found that a dose of 7.2mg can effectively induce sleep with minimal side effects in 50% patients before surgery.

In summary, the present study intends to carry out a prospective,randomized,double-blind,placebo-controlled clinical study to investigate the hypothesis that preoperative oral midazolam solution could reduce acute postoperative pain, promote early recovery, and reduce the risk of chronic pain in patients with poor sleep or anxiety before colorectal cancer surgery. It is postulated that the potential benefits of preoperative oral midazolam solution may be attributed to decreased stress levels, and lowered inflammation markers.

03

Conditions studied

  • Preoperative
  • Sleep Disturbance
  • Anxiety
  • Midazolam
  • Pain, Postoperative

Browse trials for

Keywords

  • preoperative
  • oral midazolam
  • sleep disturbance
  • anxiety
  • postoperative pain
  • colorectal cancer
04

In context

Pain, Postoperative Reclassified

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

This study's planned enrollment of 280 is above the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Sixth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 217 studies on the registry; 111 are open to participants now.

Compared within Pain, Postoperative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anxiety Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Signed of voluntarily; 2. Native Chinese speaker; 3. Age 18-60 years old, male or female; 4. 18-30 kg/m2; 5. (ASA) grade 1 or 2, (NYHA) gradeⅠor Ⅱ; 6. Non-emergency laparoscopic colorectal cancer resection; 7. General anesthesia with tracheal intubation; 8. Sleep disturbance (the Insomnia Severity Index,ISI≥15 ) or Anxiety (Generalized Anxiety Disorder scale-7,GAD-7≥10 ) from admission to surgery.

Exclusion criteria

Exclusion Criteria:

    1. for Midazolam Oral Solution (According to the Instruction for Midazolam Oral Solution); 2. High risk of Obstructive Sleep Apnea Symptoms (Total score of STOP-Bang scale ≥3 points); 3. Suspected dementia (Total score of (MMSE) according to years of education: 0 year≤19 points; 1\~6 years≤22 points; above of 6 years≤26 points); 4. Severe depressive symptom within two weeks (Total score of Patient Health Questionnaire-9 (PHQ-9)≥15); 5. History of Neurological and Psychiatric diseases (According to the electronic medical record system); 6. History of (According to the electronic medical record system); 7. History of Heart Failure (According to the electronic medical record system); 8. Intestinal obstruction(The electronic medical record system records those who currently have any type of intestinal obstruction); 9. Liver and renal insufficiency; 10. Have taken opioids or drugs that act on the central nervous system within one week; 11. Take isoenzyme inhibitors or inducers within one week (According to the Instruction for Midazolam Oral Solution); 12. Consume any alcoholic beverage within 24 hours; 13. Substance abusers (including alcohol, drugs or addictive substances); 14. Pregnant or lactating women.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

06

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Midazolam oral solution Group

    The intervention drug is midazolam oral solution at a dose of 7-10mg. The starting dosage is 7mg, with subsequent individual increases of 1mg up to a maximum dose of 10mg if patients do not achieve sleep within 30 minutes of administration. The individual dose wil be consistently maintained at the corresponding level every night until the surgery.

    Drug: Midazolam oral solution

  • Placebo comparator
    Control Group

    Placebo is a solution of midazolam oral solution that looks, tastes, and appears the same as the intervention drug, similar to the experimental group increment method.

    Other: Placebo

Interventions

  • DrugMidazolamStudies of MidazolamMidazolam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Each individual administers the midazolam oral solution nightly from enrollment to the surgry.

    Also known as: Midazolam oral solution, YICHANG HUMANWELL PHARMACEUTICAL

  • OtherPlacebo

    Each individual administers placebo solution nightly from enrollment to the surgry.

07

What researchers measure

Primary outcomes

  1. Incidence of moderate to severe pain on the first postoperative day

    NRS: Numerical Rating Scale, NRS pain score 0-3 for mild, 4-6 for moderate, 7-10 for severe; Moderate to severe pain: Mean NRS pain score ≥4; Mean NRS pain score: Mean pain is defined as the mean of NRS scores of the severest, lightest, average, and present pain within 24 hours using the Brief Pain Inventory Short version (BPIsf).

    Time frame: on the first postoperative day for Acute Postoperative Pain

Secondary outcomes

  1. Mean NRS pain score

    NRS: Numerical Rating Scale, NRS pain score 0-3 for mild, 4-6 for moderate, 7-10 for severe; Mean NRS pain score: Mean pain is defined as the mean of NRS scores of the severest, lightest, average, and present pain within 24 hours using the Brief Pain Inventory Short version (BPIsf).

    Time frame: on the first postoperative day for Acute Postoperative Pain

  2. Mean NRS pain score

    NRS: Numerical Rating Scale, NRS pain score 0-3 for mild, 4-6 for moderate, 7-10 for severe; Mean NRS pain score: Mean pain is defined as the mean of NRS scores of the severest, lightest, average, and present pain within 24 hours using the Brief Pain Inventory Short version (BPIsf).

    Time frame: on the second postoperative day for Acute Postoperative Pain

  3. Mean NRS pain score

    NRS: Numerical Rating Scale, NRS pain score 0-3 for mild, 4-6 for moderate, 7-10 for severe; Mean NRS pain score: Mean pain is defined as the mean of NRS scores of the severest, lightest, average, and present pain within 24 hours using the Brief Pain Inventory Short version (BPIsf).

    Time frame: on the third postoperative day for Acute Postoperative Pain

  4. Incidence of moderate to severe pain

    NRS: Numerical Rating Scale, NRS pain score 0-3 for mild, 4-6 for moderate, 7-10 for severe; Moderate to severe pain: Mean NRS pain score ≥4; Mean NRS pain score: Mean pain is defined as the mean of NRS scores of the severest, lightest, average, and present pain within 24 hours using the Brief Pain Inventory Short version (BPIsf).

    Time frame: on the second postoperative day for Acute Postoperative Pain

  5. Incidence of moderate to severe pain

    NRS: Numerical Rating Scale, NRS pain score 0-3 for mild, 4-6 for moderate, 7-10 for severe; Moderate to severe pain: Mean NRS pain score ≥4; Mean NRS pain score: Mean pain is defined as the mean of NRS scores of the severest, lightest, average, and present pain within 24 hours using the Brief Pain Inventory Short version (BPIsf).

    Time frame: on the third postoperative day for Acute Postoperative Pain

  6. The number of times analgesics being added

    The number of additional postoperative analgesics, by Patient-Controlled Analgesia or prescribed by doctors

    Time frame: on the first postoperative day for Acute Postoperative Pain

  7. The number of times analgesics being added

    The number of additional postoperative analgesics, by Patient-Controlled Analgesia or prescribed by doctors

    Time frame: on the second postoperative day for Acute Postoperative Pain

  8. The number of times analgesics being added

    The number of additional postoperative analgesics, by Patient-Controlled Analgesia or prescribed by doctors

    Time frame: on the third postoperative day for Acute Postoperative Pain

  9. Total scores of the questionnaire of 15-item Quality of Recovery scale

    QoR-15: 15-item Quality of Recovery scale; QoR-15 is a patient-reported measure, and is used to assess global recovery quality after surgery physiologically and psychologically. QoR-15 contents 15 items, which item is constructed by an 11-point numerical rating scale (for positive items, 0="none of the time"to 10="all of the time"; for negative items the scoring are reversed). The total scores are ranging from 0(extremely poor QoR) to 150 (excellent QoR).

    Time frame: on the first postoperative day

  10. Total scores of the questionnaire of 15-item Quality of Recovery scale

    QoR-15: 15-item Quality of Recovery scale; QoR-15 is a patient-reported measure, and is used to assess global recovery quality after surgery physiologically and psychologically. QoR-15 contents 15 items, which item is constructed by an 11-point numerical rating scale (for positive items, 0="none of the time"to 10="all of the time"; for negative items the scoring are reversed). The total scores are ranging from 0(extremely poor QoR) to 150 (excellent QoR).

    Time frame: on the second postoperative day

  11. Total scores of the questionnaire of 15-item Quality of Recovery scale

    QoR-15: 15-item Quality of Recovery scale; QoR-15 is a patient-reported measure, and is used to assess global recovery quality after surgery physiologically and psychologically. QoR-15 contents 15 items, which item is constructed by an 11-point numerical rating scale (for positive items, 0="none of the time"to 10="all of the time"; for negative items the scoring are reversed). The total scores are ranging from 0(extremely poor QoR) to 150 (excellent QoR).

    Time frame: on the third postoperative day

  12. Requirement for propofol when induction of general anesthesia

    Propofol is titrated for the purpose of achieving general anesthesia prior to colorectal cancer resection. Upon reaching the titration endpoint, indicated by an OAAS sedation score of 0, the dosage of propofol administered (in mg/kg) is documented. OAAS:Observer's Assessment Alertness/Sedation scale

    Time frame: on the day of colorectal cancer resection and general anesthesia

  13. Incidence of post-anesthesia care unit (PACU) stays longer than 1 hour

    Following the surgical procedure, the patient is relocated to the Post-Anesthesia Care Unit (PACU). Patients may be transferred to the general ward once their postoperative resuscitation meets established standards. Incidence of PACU stays longer than 1 hour is recorded.

    Time frame: on the day of colorectal cancer resection and general anesthesia

  14. The amount of additional analgesics in PACU

    The quantity of supplementary analgesic medications administered in PACU

    Time frame: on the day of colorectal cancer resection and general anesthesia

  15. Incidence of fever in the first 72 hours after surgery

    The incidence of axillary temperatures above 38℃ within 72 hours post-surgery is recorded.

    Time frame: In the third postoperative day

  16. Length of hospital stay after surgery

    Length of hospital stay after surgery:hospital stay time (days) from operation completion to actual hospital discharge

    Time frame: Days from operation completion to actual hospital discharge (expected 7 days after surgery)

  17. The financial burden in the hospital after surgery

    Medical costs from operation completion to actual hospital discharge

    Time frame: Days from operation completion to actual hospital discharge (expected 7 days after surgery)

  18. Incidence of unplanned reoperations within 30 Days after Surgery

    Incidence of unplanned reoperations within 30 Days after Surgery

    Time frame: within 30 days after surgery

  19. Incidence of unplanned admissions within 30 Days after Surgery

    Incidence of unplanned admissions within 30 Days after Surgery

    Time frame: within 30 days after surgery

  20. Total score of The Brief Pain Inventory at the 30th day after surgery

    The Brief Pain Inventory: to survey postoperative chronic pain after surgery

    Time frame: at the 30th day after surgery for chronic Postoperative Pain

  21. Total score of The Brief Pain Inventory at the 90th day after surgery

    The Brief Pain Inventory: to survey postoperative chronic pain after surgery

    Time frame: at the 90th day after surgery for chronic Postoperative Pain

  22. Total score of SF-36 at the 30th day after surgery

    SF-36: The short form (SF)-36 is an instrument to survey postoperative health status.

    Time frame: at the 30th day after surgery for postoperative health status

  23. Total score of SF-36 at the 90th day after surgery

    SF-36: The short form (SF)-36 is an instrument to survey postoperative health status.

    Time frame: at the 90th day after surgery for postoperative health status

  24. Number of patients still taking pain medication on day 30 after surgery

    Number of patients still taking pain medication on day 30 after surgery

    Time frame: on the 30th day after surgery

  25. Number of patients still taking pain medication on day 90 after surgery

    Number of patients still taking pain medication on day 90 after surgery

    Time frame: on the 90th day after surgery

  26. Incidence of post-traumatic stress disorder (PTSD) at 30 days post-surgery

    The prevalence of post-traumatic stress disorder as measured by the PC-PTSD scale at 30 days following surgical procedures. PC- PTSD:Primary Care Post traumatic Stress Disorder

    Time frame: on the 30th day after surgery

  27. Incidence of post-traumatic stress disorder (PTSD) at 90 days post-surgery

    The prevalence of post-traumatic stress disorder as measured by the PC-PTSD scale at 90 days following surgical procedures. PC- PTSD:Primary Care Post traumatic Stress Disorder

    Time frame: on the 90th day after surgery

  28. The ratio of neutrophils to lymphocytes in peripheral blood on the first day after surgery

    The ratio of neutrophils to lymphocytes in peripheral blood on the first day after surgery

    Time frame: on the first day after surgery

  29. The ratio of neutrophils to lymphocytes in peripheral blood on the third day after surgery

    The ratio of neutrophils to lymphocytes in peripheral blood on the third day after surgery

    Time frame: on the third day after surgery

  30. The ratio of platelets to lymphocytes in peripheral blood on the first day after surgery

    The ratio of platelets to lymphocytes in peripheral blood on the first day after surgery

    Time frame: on the first day after surgery

  31. The ratio of platelets to lymphocytes in peripheral blood on the third day after surgery

    The ratio of platelets to lymphocytes in peripheral blood on the third day after surgery

    Time frame: on the third day after surgery

  32. C-reactive protein levels in peripheral blood on the first day after surgery

    C-reactive protein levels in peripheral blood on the first day after surgery

    Time frame: on the first day after surgery

  33. C-reactive protein levels in peripheral blood on the third day after surgery

    C-reactive protein levels in peripheral blood on the third day after surgery

    Time frame: on the third day after surgery

  34. Opioid consumption in milligrams of intravenous morphine equivalents within three days after surgery

    Opioid consumption in milligrams of intravenous morphine equivalents within three days after surgery

    Time frame: within three days after surgery

  35. Opioid consumption in milligrams of intravenous or oral morphine equivalents within 30 days after surgery

    Opioid consumption in milligrams of intravenous or oral morphine equivalents within 30 days after surgery

    Time frame: within 30 days after surgery

  36. Opioid consumption in milligrams of intravenous or oral morphine equivalents within 90 days after surgery

    Opioid consumption in milligrams of intravenous or oral morphine equivalents within 90 days after surgery

    Time frame: within 90 days after surgery

  37. Incidence of nausea (requiring treatment) and vomiting within three days after surgery

    Incidence of nausea (requiring treatment) and vomiting within three days after surgery

    Time frame: within three days after surgery

  38. Incidence of patients mobilising on the first day after surgery

    Incidence of patients mobilising on the first day after surgery

    Time frame: on the first day after surgery

  39. time until first flatus after surgery in days

    time until first flatus after surgery in days

    Time frame: time until first flatus after surgery in days (generally, within the three days after surgery )

  40. Incidence of complications related to surgery within 30 days after surgery

    Incidence of complications related to surgery within 30 days after surgery \[ complication grade according to Clavien-Dindo(No complications,Grade I-II,Grade IIIa + IIIb,Grade IV,Grade V)\]

    Time frame: within 30 days after surgery

Other outcomes

  1. Salivary cortisol

    preoperative Salivary cortisol

    Time frame: Days from admission to the day of surgery (expected 5 days before surgery)

  2. Cytokine group

    Peripheral blood being collected before surgery

    Time frame: on the surgery day (before general anesthesia and surgery)

  3. Endocannabinoids

    Peripheral blood being collected before surgery

    Time frame: on the surgery day (before general anesthesia and surgery)

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Oct 2025, 15 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 15 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2024
First posted
May 9, 2024
StartActual
Jul 24, 2024
Primary completionEst.
Oct 2025
CompletionEst.
Dec 2025
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06407518
Responsible party
SanQing Jin (professor, Sixth Affiliated Hospital, Sun Yat-sen University) — Principal investigator
First posted
May 9, 2024
Start date
Jul 24, 2024
Primary completion
Oct 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Apr 6, 2025

Study contacts

Sanqing Jin, MD
Contact
jinsq@mail.sysu.edu.cn
0086-13719366863
Yan Zhou, MD
Contact
zhouyan8@mail3.sysu.edu.cn
0086-13632404420
sanqing Jin, MD
principal investigator · The Sixth Affiliated Hospital, Sun Yat-sen University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Midazolam

Start the discussion